查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1763891

自擴增 RNA 合成市場－全球產業規模、佔有率、趨勢、機會和預測（按產品與服務、應用、最終用戶、地區和競爭細分，2020-2030 年）

Self-amplifying RNA Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球自擴增RNA (saRNA) 合成市場規模為1.0969億美元，預計2030年將達到3.1712億美元，複合年成長率為19.33%。隨著製藥和生物技術產業擴大採用下一代RNA技術，該市場正在經歷快速成長。 saRNA相較於傳統mRNA具有關鍵優勢，其能夠在宿主細胞內自我複製，從而能夠以顯著較低的劑量實現高蛋白表達。這種高效性正推動其在傳染病、腫瘤學和罕見遺傳疾病等治療領域的應用。

市場概覽
預測期 2026-2030
2024年市場規模 1.0969億美元
2030年市場規模 3.1712億美元
2025-2030 年複合年成長率 19.33%
成長最快的領域 生物醫學研究
最大的市場 北美洲

該技術持久的治療效果，加上較低的材料要求，使其在疫苗開發、基因治療和癌症免疫治療領域中尤為具有吸引力。來自CDMO和製藥公司的投資正在推動可擴展和高精度合成平台的需求。專注於RNA的生物技術公司與研究機構之間的合作正在進一步加速創新。鑑於全球抗生素抗藥性的負擔——據估計每年導致超過127萬人死亡——saRNA在下一代疫苗和治療方案中擁有巨大的潛力，凸顯了其在未來醫療保健應用中的戰略重要性。

關鍵市場促進因素

下一代RNA療法和疫苗的需求激增

主要市場挑戰

合成方案缺乏標準化

主要市場趨勢

模組化、即插即用平台開發

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球自擴增RNA合成市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品和服務（產品{預製 saRNA、酵素和試劑、其他}、客製化合成服務）
    • 按應用（治療學開發{傳染病、腫瘤學、其他}、生物醫學研究）
    • 按最終用戶（製藥和生物技術公司、學術和研究機構、其他）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美自擴增RNA合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲自擴增RNA合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太自擴增RNA合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲自擴增RNA合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲自擴增 RNA 合成市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • GenScript Biotech Corporation
  • Creative Biogene, Inc.
  • OZ Biosciences SAS
  • BOC Sciences
  • Croyez Bioscience Co., Ltd.
  • Creative Biolabs, Inc.
  • Maravai LifeSciences Holdings, Inc.
  • Areterna LLC
  • Applied DNA Sciences, Inc.
  • Moderna, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 29618

The Global Self-amplifying RNA (saRNA) Synthesis Market was valued at USD 109.69 million in 2024 and is projected to reach USD 317.12 million by 2030, registering a CAGR of 19.33%. This market is experiencing rapid growth as the pharmaceutical and biotechnology industries increasingly adopt next-generation RNA technologies. saRNA provides a critical advantage over conventional mRNA by enabling high protein expression at significantly lower doses due to its ability to self-replicate within host cells. This efficiency is driving its use in therapeutic areas such as infectious disease, oncology, and rare genetic disorders.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 109.69 Million
Market Size 2030USD 317.12 Million
CAGR 2025-203019.33%
Fastest Growing SegmentBiomedical Research
Largest MarketNorth America

The technology's long-lasting therapeutic effects, combined with its lower material requirements, make saRNA especially attractive for vaccine development, gene therapies, and cancer immunotherapy. Investment from CDMOs and pharmaceutical firms is fueling demand for scalable and high-precision synthesis platforms. Collaborations between RNA-focused biotech companies and research institutions are further accelerating innovation. Given the global burden of antimicrobial resistance-estimated to cause over 1.27 million deaths annually-saRNA holds significant promise for next-generation vaccines and treatment solutions, underscoring its strategic importance in future healthcare applications.

Key Market Drivers

Surging Demand for Next-Generation RNA Therapeutics and Vaccines

A major driver of the saRNA synthesis market is the rising demand for advanced RNA-based therapeutics and vaccines. saRNA's self-amplifying mechanism allows for greater protein production using smaller doses than traditional mRNA, reducing overall production costs while improving therapeutic efficacy. This is particularly beneficial in high-priority therapeutic fields such as infectious diseases, rare disorders, and oncology.

The proven success of RNA technologies in clinical settings has strengthened industry confidence and prompted greater integration of saRNA into commercial pipelines. As biopharma companies seek more cost-efficient and potent treatment platforms, saRNA's unique attributes position it as a transformative tool in the future of medicine.

Key Market Challenges

Lack of Standardization in Synthesis Protocols

The absence of standardized protocols is a key challenge impacting the scalability and reproducibility of saRNA production. saRNA molecules are more complex and larger than conventional mRNA, requiring meticulous optimization of synthesis parameters such as capping, dsRNA reduction, and purification techniques.

Inconsistent practices across labs and CDMOs-due to reliance on proprietary processes and varying reagent quality-result in variability in product quality. This variability poses risks during clinical development and limits the ability to establish uniform manufacturing practices across the industry, especially when scaling from research-grade to clinical-grade production.

Key Market Trends

Modular and Plug-and-Play Platform Development

A significant trend shaping the saRNA synthesis market is the advancement of modular and plug-and-play development platforms. These systems are engineered to streamline the design, production, and scalability of saRNA constructs by enabling rapid interchange of functional elements-such as replicase sequences, antigen regions, untranslated regions (UTRs), and capping mechanisms-without needing to alter the core RNA structure.

This flexibility accelerates the development cycle, supports swift adaptation to emerging pathogens or mutations, and enhances efficiency in therapeutic discovery. Such platforms are particularly valuable in addressing rapidly evolving disease targets and are instrumental in improving responsiveness during public health emergencies.

Key Market Players

  • GenScript Biotech Corporation
  • Creative Biogene, Inc.
  • OZ Biosciences SAS
  • BOC Sciences
  • Croyez Bioscience Co., Ltd.
  • Creative Biolabs, Inc.
  • Maravai LifeSciences Holdings, Inc.
  • Areterna LLC
  • Applied DNA Sciences, Inc.
  • Moderna, Inc.

Report Scope:

In this report, the Global Self-amplifying RNA Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Self-amplifying RNA Synthesis Market, By Product & Service:

  • Products
    • Premade saRNA
    • Enzymes & Reagents
    • Others
  • Custom Synthesis Services

Self-amplifying RNA Synthesis Market, By Application:

  • Therapeutics Development
    • Infectious Diseases
    • Oncology
    • Others
  • Biomedical Research

Self-amplifying RNA Synthesis Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others

Self-amplifying RNA Synthesis Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Self-amplifying RNA Synthesis Market.

Available Customizations:

Global Self-amplifying RNA Synthesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Self-amplifying RNA Synthesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (Products {Premade saRNA, Enzymes & Reagents, Others}, Custom Synthesis Services)
    • 5.2.2. By Application (Therapeutics Development {Infectious Diseases, Oncology, Others}, Biomedical Research)
    • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Self-amplifying RNA Synthesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Self-amplifying RNA Synthesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Self-amplifying RNA Synthesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Self-amplifying RNA Synthesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Self-amplifying RNA Synthesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Self-amplifying RNA Synthesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Self-amplifying RNA Synthesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Self-amplifying RNA Synthesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Self-amplifying RNA Synthesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Self-amplifying RNA Synthesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Self-amplifying RNA Synthesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Self-amplifying RNA Synthesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Self-amplifying RNA Synthesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Self-amplifying RNA Synthesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Self-amplifying RNA Synthesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Self-amplifying RNA Synthesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Self-amplifying RNA Synthesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Self-amplifying RNA Synthesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Self-amplifying RNA Synthesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Self-amplifying RNA Synthesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Self-amplifying RNA Synthesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Self-amplifying RNA Synthesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Self-amplifying RNA Synthesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Self-amplifying RNA Synthesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GenScript Biotech Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Creative Biogene, Inc.
  • 15.3. OZ Biosciences SAS
  • 15.4. BOC Sciences
  • 15.5. Croyez Bioscience Co., Ltd.
  • 15.6. Creative Biolabs, Inc.
  • 15.7. Maravai LifeSciences Holdings, Inc.
  • 15.8. Areterna LLC
  • 15.9. Applied DNA Sciences, Inc.
  • 15.10. Moderna, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer